Like many other major pharmaceutical companies, AstraZeneca is facing a series of patent cliffs for key treatments in its portfoilio.

Backed by Perceptive Xontogeny Venture Funds and venBio Partners, the new biotech will make genetic medicines that don’t rely ...

AstraZeneca and its partner Daiichi Sankyo have won approval from U.S. regulators for their precision drug Datroway to treat ...

The US Food and Drug Administration (FDA) has approved AstraZeneca and Daiichi Sankyo's Datroway (Datopotamab deruxtecan) for adults with locally advanced or metastatic epidermal growth factor ...

Daiichi Sankyo’s Lixiana was a late entrant to the novel oral anticoagulant (NOAC) category, but the Japanese drugmaker hopes new data in atrial fibrillation (AFib) could accelerate its growth.

Daiichi Sankyo Company, Limited (OTCPK:DSKYF) FY2024 Earnings Conference Call April 25, 2025 2:00 AM ET Company Participants Kentaro Asakura - VP of Corporate Communications Hiroyuki Okuzawa ...

Narrow-moat Daiichi Sankyo’s second-quarter earnings were in line with our expectations. Management revised its full-year guidance revenue upward by 5% since its April forecast and core ...

Narrow-moat Daiichi Sankyo's first-quarter earnings exceeded our expectations due to strong performance across its businesses, including Enhertu and Lixiana sales as well as its American Regent ...

Daiichi Sankyo is a Japanese pharmaceutical company known for its flagship products Lixiana and Enhertu. Enhertu is becoming a popular treatment for breast cancer, based on technology that is ...

MUNICH--(BUSINESS WIRE)--Daiichi Sankyo Europe, (hereafter, Daiichi Sankyo) today announced new edoxaban data being presented at The European Society of Cardiology Congress 2022. These include ...

Nachrichten»Daiichi Sankyo: New data support the use of LIXIANA (edoxaban) in complex patient populations with atrial fibrillation (AF) Push Mitteilungen Business Wire 28.08.2021 14:52 Uhr 1.523 ...

DAIICHI SANKYO Co., Ltd. assume no responsibility for the updating of such forward-looking statements about future developments of the sector, legal and business conditions and the company.